Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure

Journal of Cardiology

Volumn 61, Issue 4, 2013, Pages 267-274

  Matsuzaki, Masunori ^a   Yamamoto, Kazuhiro ^b   Yano, Masafumi ^a   Nakamura, Koki ^c   Miyata, Yuko ^c   Sugiura, Kenkichi ^c   Nakata, Emi ^c   Tsutsui, Hiroyuki ^d  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Brain natriuretic peptide; Candesartan; Heart failure; Left ventricular ejection fraction

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CANDESARTAN;

ACUTE PYELONEPHRITIS; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; JAPANESE; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; OPEN STUDY; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; TREATMENT DURATION; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZIMIDAZOLES; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TETRAZOLES; TIME FACTORS;

EID: 84875674589     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.12.004     Document Type: Article

References (14)

1. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Strömberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933-989.
2. Jessup M., Abraham W.T., Casey D.E., Feldman A.M., Francis G.S., Ganiats T.G., Konstam M.A., Mancini D.M., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
3. Shiba N., Nochioka K., Miura M., Kohno H., Shimokawa H. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan: first report from the CHART-2 study. Circ J 2011, 75:823-833. CHART-2 Investigators.
4. mhlw.go.jp [Internet]. Trends in leading causes of death [updated 2011 September 1; cited 2011 September 29]. Tokyo: Ministry of Health, Labour and Welfare. Available from: [accessed July 3, 2012]. http://www.mhlw.go.jp/english/database/db-hw/populate/dl/03.pdf.
5. Vauquelin G., Fierens F., Van Liefde I. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl 2006, 24:S23-S30.
6. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003, 5:669-677. Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators.
7. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781. CHARM Investigators and Committees.
8. Goda A., Yamashita T., Suzuki S., Ohtsuka T., Uejima T., Oikawa Y., Yajima J., Koike A., Nagashima K., Kirigaya H., Sagara K., Ogasawara K., Isobe M., Sawada H., Aizawa T. Heart failure with preserved versus reduced left ventricular systolic function: a prospective cohort of Shinken Database 2004-2005. J Cardiol 2010, 55:108-116.
9. Sato Y., Fujiwara H., Takatsu Y. Biochemical markers in heart failure. J Cardiol 2012, 59:1-7.
10. Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., Glazer R.D., Tognoni G., Cohn J.N. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003, 107:1278-1283. Val-HeFT Investigators.
11. Granger C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., Ostergren J., Pfeffer M.A., Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative Trial. Lancet 2003, 362:772-776. CHARM Investigators and Committees.
12. McMurray J.J., östergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., Olofsson B., Yusuf S., Pfeffer M.A. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added Trial. Lancet 2003, 362:767-771. CHARM Investigators and Committees.
13. Anand I.S., Fisher L.D., Chiang Y.-T., Latini R., Masson S., Maggioni A.P., Glazer R.D., Tognoni G., Cohn J.N. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003, 107:1278-1283. Val-HeFT Investigators.
14. Konstam M.A., Neaton J.D., Dickstein K., Drexler H., Komajda M., Martinez F.A., Riegger G.A., Malbecq W., Smith R.D., Guptha S., Poole-Wilson P.A. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009, 374:1840-1848. HEAAL Investigators.